Aspire Biopharma
ASBP
52 hedge funds and large institutions have $241M invested in Aspire Biopharma in 2022 Q2 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.07% more ownership
Funds ownership: 0% → 0.07% (+0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$21M |
| 2 |
GCL
Glazer Capital LLC
New York
|
+$20.4M |
| 3 |
SCM
Saba Capital Management
New York
|
+$19.6M |
| 4 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$13.4M |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$11.9M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $4K | – | – | – |
|
52
Bank of Montreal
Toronto,
Ontario, Canada
| $1.36K | +$1.35M | +113 | New |
|
|
MF
53
Magnetar Financial
Evanston,
Illinois
| $1.31K | +$1.32M | +110 | New |
|
ASBP Hedge Fund Activity: Q2 2022 in Review
52 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q2 2022, worth a combined $241M.
Buyers outnumbered sellers: 52 funds opened new ASBP positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $21M.
- 52 institutional investors held Aspire Biopharma (ASBP) as of Q2 2022, up from 0 in Q1 2022.
- Funds reported $241M of Aspire Biopharma stock for Q2 2022.
- 52 funds opened new Aspire Biopharma positions in Q2 2022 and 0 closed out, a net change of +52 holders.
- The largest Aspire Biopharma buyer in Q2 2022 was Adage Capital Partners, an estimated $21M added.
Based on aggregated 13F filings for Q2 2022.